Catalog No.
RVV00506
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2 (2019-nCoV)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
S2 Protein,Spike protein S2,Spike protein S2',Spike glycoprotein,S glycoprotein,E2,Peplomer protein,Spike protein S1,S
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
ELISA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1B3
Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075
mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract., PMID:40342969
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243
Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site., PMID:40198676
Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428
Determinants and dynamics of the seroprevalence of anti-SARS-CoV-2 antibodies in Poland., PMID:40097104
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine., PMID:40088511
Unveiling the Complete Spectrum of SARS-CoV-2 Fusion Stages by In Situ Cryo-ET., PMID:40060467
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants., PMID:40000611
NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733
Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection., PMID:39990164
High rate of RNAemia and impaired immunity in patients with immunodeficiency in the vaccination era., PMID:39985863
Concordance of maternal and cord blood SARS-COV-2 immunoglobulin seropositivity after COVID-19 infection or vaccination in pregnancy., PMID:39973524
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941
A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548
Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad-spectrum neutralizing antibodies against SARS-CoV-2 and its variants., PMID:39931737
A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay., PMID:39929938
Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599
Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera., PMID:39827186
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice., PMID:39774966
Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis., PMID:39769415
Structural Immunology of SARS-CoV-2., PMID:39731211
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults., PMID:39723823
Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients., PMID:39678346
SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization., PMID:39621785
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673
Display of Native SARS-CoV-2 Spike on Mammalian Cells to Measure Antibody Affinity and ADCC., PMID:39600972
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795
A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection., PMID:39548371
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection., PMID:39516286
Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens., PMID:39337303
Discovery and characterization of a pan-betacoronavirus S2-binding antibody., PMID:39326419
Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site., PMID:39290379
Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection., PMID:39248629
A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein., PMID:39242614
Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA.1 variants., PMID:39216601
Formulation Development of a COVID-19 Recombinant Spike Protein-Based Vaccine., PMID:39203956
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens., PMID:39191724
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters., PMID:39162540
XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection., PMID:39156763
Structure and inhibition of SARS-CoV-2 spike refolding in membranes., PMID:39146425
Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein., PMID:39125749
Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients., PMID:39122634
For research use only. Not for human or drug use.
